RU2013127115A - Комбинированная терапия при в-клеточных лимфомах - Google Patents

Комбинированная терапия при в-клеточных лимфомах Download PDF

Info

Publication number
RU2013127115A
RU2013127115A RU2013127115/15A RU2013127115A RU2013127115A RU 2013127115 A RU2013127115 A RU 2013127115A RU 2013127115/15 A RU2013127115/15 A RU 2013127115/15A RU 2013127115 A RU2013127115 A RU 2013127115A RU 2013127115 A RU2013127115 A RU 2013127115A
Authority
RU
Russia
Prior art keywords
antibody
combination therapy
seq
amino acid
acid sequence
Prior art date
Application number
RU2013127115/15A
Other languages
English (en)
Russian (ru)
Inventor
Роналд ХЕРБСТ
Элизабет К. УОРД
Кэтлин Филлипс МакКИВЕР
Original Assignee
МЕДИММЬЮН, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МЕДИММЬЮН, ЭлЭлСи filed Critical МЕДИММЬЮН, ЭлЭлСи
Publication of RU2013127115A publication Critical patent/RU2013127115A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2013127115/15A 2010-11-15 2011-11-14 Комбинированная терапия при в-клеточных лимфомах RU2013127115A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41377110P 2010-11-15 2010-11-15
US61/413,771 2010-11-15
PCT/US2011/060520 WO2012067981A1 (en) 2010-11-15 2011-11-14 Combination therapy for b cell lymphomas

Publications (1)

Publication Number Publication Date
RU2013127115A true RU2013127115A (ru) 2014-12-27

Family

ID=46084355

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013127115/15A RU2013127115A (ru) 2010-11-15 2011-11-14 Комбинированная терапия при в-клеточных лимфомах

Country Status (11)

Country Link
US (1) US20130330328A1 (enExample)
EP (1) EP2640416A4 (enExample)
JP (1) JP2013543869A (enExample)
KR (1) KR20130130726A (enExample)
CN (1) CN103228291A (enExample)
AU (1) AU2011329161A1 (enExample)
CA (1) CA2817842A1 (enExample)
MX (1) MX2013005270A (enExample)
RU (1) RU2013127115A (enExample)
SG (1) SG190254A1 (enExample)
WO (1) WO2012067981A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2981046T3 (es) * 2016-05-30 2024-10-07 Incyte Corp Métodos para predecir el beneficio terapéutico de una terapia anti-CD19 en pacientes
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
US20250215081A1 (en) * 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1853718E (pt) * 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US8323653B2 (en) * 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Also Published As

Publication number Publication date
JP2013543869A (ja) 2013-12-09
CN103228291A (zh) 2013-07-31
SG190254A1 (en) 2013-06-28
CA2817842A1 (en) 2012-05-24
EP2640416A4 (en) 2014-04-23
US20130330328A1 (en) 2013-12-12
EP2640416A1 (en) 2013-09-25
WO2012067981A1 (en) 2012-05-24
KR20130130726A (ko) 2013-12-02
MX2013005270A (es) 2013-10-25
AU2011329161A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
ES2731548T3 (es) Composiciones que comprenden anticuerpos anti-CD38 y lenalidomida
EP2648747B1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
RU2756010C2 (ru) Комбинация антитела к CD19 и ингибитора тирозинкиназы брутона и их применение
US12194095B2 (en) Combinations and uses thereof
ES2808565T3 (es) Composiciones que comprenden anticuerpos anti-CD38 y carfilzomib
HRP20231156T1 (hr) Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
JP2017528462A5 (enExample)
KR102115203B1 (ko) 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
IL224915A (en) Anti-cd38 antibody and nalidomide or bortezomib for the treatment of multiple myeloma and nhl
FI3778641T3 (fi) Bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat CD3:a ja CD20:tä, ja niiden käyttöjä
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP2014525926A5 (enExample)
JP2013543869A5 (enExample)
HK40069168A (en) Combinations and uses thereof
RU2021128914A (ru) Ингибиторы пути il-4/il-13 для повышенной эффективности при лечении злокачественных новообразований
TW201315461A (zh) 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之抗腫瘤組合

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160314